ACADIA PHARMACEUTICALS INC
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the Company’s last fiscal quarter, the following officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the Exchange Act))adopted orterminated a “Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K, as follows:
On May 28, 2026, Mark C. Schneyer, Executive Vice President and Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale of up to 105,328 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is from November 6, 2026 until July 31, 2027, or earlier if and when all transactions under the trading arrangement are completed.
On June 1, 2026, Thomas Garner, Executive Vice President and Chief Commercial Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale of up to 88,771 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is from November 6, 2026 until April 1, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.